KDR and neoplasm: Afatinib inhibited LYVE-1, VEGFR2, VEGFR3, VEGFC, VEGF, and CCR7 expression in a dose-dependent manner in HCC827 xenograft tumour tissues, and these results demonstrated the anti-lymphangiogenic action of Afatinib (Figure 6C).